Table 2 Characteristics of the subjects
From: SPARC: a new approach to quantifying gait smoothness in patients with Parkinson’s disease
Healthy Controls | Patients with Parkinson’s Disease | p-value | Non-fallers | Fallers | p-value | |
|---|---|---|---|---|---|---|
# of subjects | 39 (19) | 101 (24) | 64 | 25 | ||
Age (years) | 77.8 ± 3.9 (76.6 ± 1.4) | 64.5 ± 9.3 (75.1 ± 2.2) | < 0.001 0.147 | 63.7 ± 9.8 | 67.1 ± 9.2 | 0.14 |
Gender (% women) | 64 (63) | 24 (25) | < 0.001 (0.011) | 20 | 0 | 0.44 |
Height (cm) | 163.1 ± 6.5 (163.0 ± 6.3) | 169.4 ± 8.8 (167.1 ± 9.9) | < 0.001 (0.107) | 170.7 ± 8.9 | 168.2 ± 8.8 | 0.24 |
Weight (kg) | 71.3 ± 13.2 (68.5 ± 12.6) | 76.5 ± 11.9 (77.0 ± 10.8) | 0.11 (0.030) | 75.9 ± 10.5 | 80.2 ± 14.2 | 0.12 |
UPDRS Part III (motor) | 0 | 39.8 ± 12.9 (42.6 ± 11.9) | – | 39.8 ± 13.6 | 41.3 ± 10.6 | 0.97 |
Disease duration (years) | 0 | 5.4 ± 3.3 (5.2 ± 2.3) | – | 5.1 ± 2.8 | 6.7 ± 4.4 | 0.02 |
Levodopa equivalent dose | 0 | 520.3 ± 314.4 (499.0 ± 300.8) | – | 480.0 ± 271.6 | 582.3 ± 348.0 | 0.18 |